Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AGEN1423 and Botensilimab +/- Chemotherapy in Advanced Pancreatic Cancer
NCT05632328Phase 2Active, not recruiting
- Start
- Aug 2024
- Primary completion
- Aug 2026
- Modality
- Antibody Conjugates, Engineered Antibody Formats, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of dalutrafusp alfa in pancreatic ductal adenocarcinoma (PDAC). Started Aug 2024; status: active, not recruiting.
02
Drugs
dalutrafusp alfa
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT05632328.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05632328.